[1] Mandell L A, Wunderink R G, Anzueto A,et al. Infectious Diseases Society of America/ American Thoracic Society consensus guidelines on the man-agement of community-acquired pneumonia in adults[J]. Clin Infect Dis,2007,44(Suppl 2):S27-72. [2] Workowski K A, Berman S. Sexually transmitted diseases treatment guidelines[J]. MMWR Recomm Rep,2010. [3] WHO. Management of the child with a serious infection or severe malnutrition: Guidelines for care at the first referral level in developing countries[B/OL].[2015-03-05]. http://www.whoint/maternal_child_adolescent/documents/fch_cah_00_1/en/. [3] WHO. Dept.of Child and Adolescent Health and Development UNICEF. Management of the child with a serious infection or severe malnutrition: guidelines for care at the first-referral level in developing countries[M].Geneva:World Health Organization,2000:55. [4] 中华医学会,中华医院管理学会药事管理专业委员会,中国药学会医院药学专业委员会,等.抗菌药物临床应用指导原则[J].中华医学杂志,2004,84(22):1857-1862. [5] Schaed U B,Wedgwoed-Krucko J,Tschaeppeler H.Reversible ceftfia-xone-associated biliary pseudolithiasis in children[J].The Lancet,1988,2(8625):1411- 1413. [6] Cochat P, Cochat N, Jouvenet M, et al. Ceftriaxone-associated nephrolithiasis[J]. Nephrol Dial Transplant, 1990, 5(11): 974-976. [7] 许建文,付群.头孢曲松钠与含钙注射液不恰当配伍致药物反应3例[J].儿科药学杂志,2004,10(1):63-63. [8] Shiffman M L, Keith F B, Moore E W. Pathogenesis of ceftriaxone-associated biliary sludge. In vitro studies of calcium-ceftriaxone binding and solubility[J]. Gastroenterology, 1990,99(6):1772-1778. [9] Lozanovski V J, Gucev Z, Avramoski V J, et al. Ceftriaxone associated urolithiasis in a child with hypercalciuria[J]. Hippokratia, 2011,15(2):181-183. [10] Chutipongtanate S,Thongboonkerd V.Ceftriaxone crystallization and its potential role in kidney stone formation[J].Biochemical and Biophysical Research Communications, 2011,406(3):396-402. [11] Gargollo P C, Barnewolt C E, Pediatric ceftriaxone nephrolithiasis[J]. J Urol, 2005,173(2): 577-578. [12] Nakai Y, Tokuyama E, Yoshida M, et al. Prediction of incompatibility of ceftriaxone sodium with calcium ions using the ionic product[J]. Yakugaku Zasshi,2010,130(1):95-102. [13] 国家食品药品监督管理局. 关于修订头孢曲松钠说明书中警示语和注意事项的通知(急件)[EB/OL]. (2007-02-15)[2014-12-18].http://former.sfda.gov.cn/cmsweb/webportal/W473/A64019347.html. [14] FDA.Information for Healthcare Professionals: Ceftriaxone (marketed as Rocephin) 9/2007 [EB/OL]. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProv-iders/DrugSafetyInformationforHeathcareProfessionals/ucm134328.htm,9/2007-18/12/2014. [15] FDA.Information for Healthcare Professionals: Ceftriaxone(marketed as Rocephin and generics) [EB/OL].(2009-04-21)[2014-12-18].http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationfor-HeathcareProfessionals/ucm084263.htm. [16] Bradley J S, Wassel R T, Lee L, et al. Intravenous Ceftriaxone and Calcium in the Neonate: Assessing the Risk for Cardiopulmonary Adverse Events[J]. Pediatrics,2009 ,123(4):e609-613. [17] 马红梅,张洪全,王艺红,等.注射用头孢曲松钠致假性结石的临床观察[J].基层医学论坛,2010,14(31):998-999. [18] Palanduz A,Yalcin I,Tonquc E.Sonographic assessment of ceftriaxone-associated biliary pseudolithiasis in children[J].Journal of Clinical Ultrasound,2000,28(4):166-168. [19] Avci Z,Koktener A,Uras N,et al. Nephrolithiasis associated with ceftriaxone therapy: a prospective study in 51 children[J]. Arch Dis Child,2004,89(11):1069-1072. [20] 梅丹,傅强,王强,等.国产和进口口服钙制剂对体内钙水平影响的比较[J].中国药学杂志,1998, 33 (6):350-354. [21] Cochat P, Cochat N, Jouvenet M, et al. Ceftriaxone-associated nephrolithiasis[J].Nephrol Dial Transplant ,1990,5(11):974-976. [22] 王强,张凡,梅丹,等.关于修改头孢曲松说明书一事的探讨[J].中国医院药学杂志, 2008, 28(8): 659-662. [23] Barry M,Brenner M D. Brenner & Rector's The Kidney[J]. American Journal of Kidney Diseases,2000,36(4):875-876. [24] 张威,赵海涛,张晓琳,等.头孢曲松钠注射液致儿童假性结石2例[J].中国药物应用与监测,2011,8(2):126-127. [25] Xiaoming Cong, Xiaojian Gu, Xizhao Sun, et al. Possible Function of Urinary pH and Citrate on the Ceftriaxone-induced Nephr-olithiasis[J]. Urology, 2014,83(1):63-67. |